Výsledky vyhledávání

Akademický článek

Miedema Calculator: A thermodynamic platform for predicting formation enthalpies of alloys within framework of Miedema’s Theory

Autor: Zhang, R.F., Zhang, S.H., He, Z.J., Jing, J., Sheng, S.H.

Publikováno v: In Computer Physics Communications December 2016 209:58-69

Zobrazit plný text záznamu

Akademický článek

Origin of different plastic resistance of transition metal nitrides and carbides: Stiffer yet softer

Autor: Zhang, R.F., Sheng, S.H., Veprek, S.

Publikováno v: In Scripta Materialia June 2013 68(12):913-916

Zobrazit plný text záznamu

Guselkumab in biologic-naive patients with active psoriatic arthritis (DISCOVER-2): a double-blind, randomised, placebo-controlled phase 3 trial

Autor: Mease, P.J., Rahman, P., Gottlieb, A.B., Kollmeier, A.P., Hsia, E.C., Xu, X.L., Sheng, S.H., Agarwal, P., Zhou, B., Zhuang, Y.L., Heijde, D. van der, McInnes, I.B., Discover-2 Study Grp

Publikováno v: The Lancet, 395(10230), 1126-1136. ELSEVIER SCIENCE INC

Background:\ud The interleukin-23 (IL-23)/T-helper 17 cell pathway is implicated in psoriatic arthritis pathogenesis. Guselkumab, an IL-23 inhibitor that specifically binds the IL-23 p19 subunit, significantly and safely improved psoriatic arthritis

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87f56927a5078f174fa4d4b31a7cc05a
https://doi.org/10.1016/s0140-6736(20)30263-4

Zobrazit plný text záznamu

Long-term efficacy and safety of guselkumab, a monoclonal antibody specific to the p19 subunit of interleukin-23, through two years: results from a phase III, randomized, double-blind, placebo-controlled study conducted in biologic-naive patients with active Psoriatic Arthritis

Autor: McInnes, I.B., Rahman, P., Gottlieb, A.B., Hsia, E.C., Kollmeier, A.P., Xu, X.L., Jiang, Y.S., Sheng, S.H., Shawi, M., Chakravarty, S.D., Heijde, D. van der, Mease, P.J.

Publikováno v: Arthritis & Rheumatology, 74(3), 475-485. WILEY

Objective To assess long-term efficacy and safety of guselkumab, an interleukin-23 p19 subunit (IL-23p19) inhibitor, in patients with active psoriatic arthritis (PsA) from the phase III DISCOVER-2 trial. Methods In the DISCOVER-2 trial, patients with

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=narcis______::bf491dbe6c60ff45c19ca24380da1779
http://hdl.handle.net/1887/3276429